3 results
Approved WMOCompleted
To characterize the safety, tolerability, and recommended phase 2 dose (RP2D) of each combination partner used with ruxolitinib (Part 1)To evaluate the preliminary efficacy of each novel ruxolitinib combination treatment arm (Parts 2 & 3)
Approved WMOCompleted
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months
Approved WMORecruiting
To study the effect of crizanlizumab on the hemodynamics of the cerebral vasculature (CBF and CVR)